Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Secondary treatment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12,913 result(s) found for: Secondary treatment. Displaying page 1 of 646.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-006645-41 Sponsor Protocol Number: SLAZ-Heuvel Start Date*: 2008-06-13
    Sponsor Name:Sint Lucas Andreas Hospital
    Full Title: The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
    Medical condition: Secondary hyperparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003056-36 Sponsor Protocol Number: CBAF312A2304 Start Date*: 2012-10-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro...
    Medical condition: Secondary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) IE (Completed) DE (Prematurely Ended) CZ (Completed) SK (Completed) NL (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Completed) SE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) LV (Completed) GR (Completed) LT (Completed) EE (Completed) BE (Prematurely Ended) PL (Completed) BG (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004136-30 Sponsor Protocol Number: 20130213 Start Date*: 2014-03-05
    Sponsor Name:KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
    Full Title: A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    18.0 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Completed) BE (Completed) AT (Completed) ES (Completed) PT (Completed) LT (Completed) PL (Completed) CZ (Completed) DK (Completed) LV (Completed) DE (Completed) GR (Completed) HU (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004436-36 Sponsor Protocol Number: Rituximab1.5 Start Date*: 2013-04-19
    Sponsor Name:Odense University Hospital
    Full Title: A prospective pilotstudy of immunological and radiological effects of intrathecal rituximab in patients with secondary progressive multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000178-24 Sponsor Protocol Number: W2021.040 Start Date*: 2023-10-20
    Sponsor Name:
    Full Title: Active vitamin D for secondary hyperparathyroidism after bariatric surgery: a multicenter randomized controlled trial.
    Medical condition: patients with secondary hyperparathyroidism after Roux-en-Y gastric bypass surgery (RYGB).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005051-28 Sponsor Protocol Number: 20140336 Start Date*: 2016-08-22
    Sponsor Name:Amgen Inc
    Full Title: An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to less than 18 Years with Sec...
    Medical condition: Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) LT (Completed) GB (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-002075-40 Sponsor Protocol Number: 20050182 Start Date*: 2006-10-04
    Sponsor Name:Amgen Inc.
    Full Title: EVOLVE - Evaluation Of Cinacalcet HCl Therapy to Lower Cardiovascular Events
    Medical condition: Secondary hyperparathyroidism (HPT) in subjects with chronic kidney disease (CKD) receiving maintenance hemodialysis.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) AT (Completed) DE (Completed) IE (Completed) BE (Completed) PT (Completed) DK (Completed) GB (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-007017-76 Sponsor Protocol Number: 01PTHi Start Date*: 2009-03-24
    Sponsor Name:Josep M Cruzado
    Full Title: Estudio prospectivo, randomizado para comparar paratiroidectomía subtotal versus cinacalcet en el tratamiento del hiperparatiroidismo secundario persistente post trasplante renal.
    Medical condition: Hiperparatiroidismo secundario post trasplante renal
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011378-14 Sponsor Protocol Number: M10-967 Start Date*: 2009-11-03
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH with Paricalcitol-centered Therapy vs. Cinacalcet Therapy with Low-dose Vitamin D in Hemodialysis Patients with Secondary H...
    Medical condition: Secondary hyperparathyroidism (SHPT)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020708 Hyperparathyroidism secondary LLT
    12.0 10020708 Hyperparathyroidism secondary PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) NL (Completed) ES (Completed) PT (Completed) GB (Completed) SE (Completed) IT (Completed) GR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002808-41 Sponsor Protocol Number: 20120231(KAI-4169-008) Start Date*: 2013-01-22
    Sponsor Name:KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
    Full Title: A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemod...
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    16.1 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) CZ (Completed) GB (Completed) SE (Completed) ES (Completed) IT (Completed) AT (Completed) PL (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-001043-22 Sponsor Protocol Number: HECT01206 Start Date*: 2007-11-21
    Sponsor Name:Genzyme Europe BV
    Full Title: A Multicenter, Open-Label Study of Hectorol (doxercalciferol capsules) for the Treatment of Secondary Hyperparathyroidism in Stage 3 or Stage 4 Chronic Kidney Disease (CKD) Patients
    Medical condition: Secondary hyperparathyroidism in Stage 3 or Stage 4 Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004958-18 Sponsor Protocol Number: 20130356 Start Date*: 2014-07-14
    Sponsor Name:Amgen, Inc.
    Full Title: A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis
    Medical condition: Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed) IT (Completed) HU (Completed) ES (Completed) BE (Completed) CZ (Completed) PT (Completed) DE (Completed) Outside EU/EEA GR (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-001307-16 Sponsor Protocol Number: SIC Start Date*: 2020-04-01
    Sponsor Name:Fundación para la Investigación Biomédica Hospital Ramón y Cajal
    Full Title: Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to COVID-19.
    Medical condition: Adult respiratory distress syndrome (ARDS) secondary to SARS-CoV-2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001326-25 Sponsor Protocol Number: ACA-SPAI-11-24 Start Date*: 2013-07-25
    Sponsor Name:Fundación SENEFRO
    Full Title: Efficacy and safety of paricalcitol in the reduction of secondary hyperparathyroidism after renal transplantation.
    Medical condition: Secondary hyperparathyroidism after renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    16.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-004558-34 Sponsor Protocol Number: 20070360 Start Date*: 2008-12-17
    Sponsor Name:Amgen Inc
    Full Title: Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination with Low Dose Vitamin D for the Treatment of Subjects with Secondary Hyperparathyroidism (SHPT) Recently ...
    Medical condition: Treatment of secondary hyperparathyroidism (SHPT) _______________________________________________ Tratamiento del hiperparatiroidismo secundario (HPTS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed) GB (Completed) BE (Completed) IT (Completed) IE (Completed) NO (Completed) GR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-005981-37 Sponsor Protocol Number: 8. udgave; 6. september 2006 Start Date*: 2006-12-20
    Sponsor Name:Roskilde Amts Sygehus
    Full Title: Behandling af sekundær hyperparathyreoidisme hos uræmiske patienter. En sammenlignenede undersøgelse mellem virkningen af alfacalcidol og paricalcitol.
    Medical condition: Secondary hyperparathyroidism is a common feature in patients with chronic kidney disease. Reduced synthesis of active vitamin D contributes to secondary hyperparathyroidism. Therefore we primaril...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004929-33 Sponsor Protocol Number: SiccaIkervis Start Date*: 2018-12-05
    Sponsor Name:KH Hietzing, Department of Ophthalmology
    Full Title: Effect of Ciclosporin eyedrops on ocular symptoms and optical image quality in patients with primary or secondary Sjögren syndrome
    Medical condition: primary or secondary Sjögren Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003563-38 Sponsor Protocol Number: 20140159 Start Date*: 2015-04-21
    Sponsor Name:Amgen, Inc.
    Full Title: A Multicenter Single-arm Extension Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidn...
    Medical condition: Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) HU (Completed) CZ (Completed) ES (Completed) BE (Completed) SK (Completed) FR (Completed) Outside EU/EEA GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002659-28 Sponsor Protocol Number: 20160428 Start Date*: 2017-11-10
    Sponsor Name:Amgen Inc.
    Full Title: An open-label, Randomized, Single-dose, 2-Period, "-Treatment Crossover Study to Assess the Bioequivalence of Cinacalcet Capsule (Administered as Six of the 5 mg Cinacalcet Capsules) with 30 mg Com...
    Medical condition: Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and for the treatment of hypercalcemia in patients with parathyroid carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005034-66 Sponsor Protocol Number: 20070293 Start Date*: 2014-11-13
    Sponsor Name:Amgen, Inc.
    Full Title: An Open-label, Randomized, Single-dose, 3-period, 3-treatment Crossover Study to Assess the Comparative Bioavailability of 5mg Cinacalcet Capsules to the 30mg Commercial Formulation Cinacalcet Tabl...
    Medical condition: Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and for the treatment of hypercalcemia in patients with parathyroid carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 16:47:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA